Related Experiment Video
Updated: Jan 11, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Structure-Guided Discovery of Drug-like Compounds Targeting HPV16 E6 for Antiviral Therapy Development
Jingying Shang1, Qifan Jiang2, Ting Liu1
1Department of Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Background:
Human papillomavirus type 16 (HPV16) E6 oncoprotein is a key factor in the progression of cervical and other HPV-related cancers. Targeting E6 with small molecule inhibitors represents a promising strategy for the development of novel antiviral therapies.
Objectives:
This study aimed to discover and characterize small-molecule compounds that exhibit high affinity for HPV16 E6, possess favorable drug-like properties, and inhibit HPV16 E6, using advanced computational approaches.
Materials And Methods:
We integrated molecular dynamics simulations to capture the conformational flexibility of HPV16 E6 and employed structure-based virtual screening to identify potential inhibitors from a large chemical library. The binding stability and interaction patterns of selected compounds were evaluated through molecular docking, binding free energy calculations, and extended molecular dynamics simulations. In silico ADMET profiling was performed to assess the pharmacokinetic and toxicity properties of the top candidates.
Results:
Nine lead compounds demonstrated stable binding to a key functional residue (CYS51) of HPV16 E6, with strong theoretical binding affinities confirmed by MM-GBSA calculations and molecular dynamics analysis. ADMET predictions indicated that most candidates possessed favorable pharmacokinetic profiles, although two compounds showed potential toxicity concerns.
Conclusion:
Our findings provide a robust computational framework for the identification of drug-like small molecules targeting HPV16 E6, offering promising candidates for further development as antiviral agents against HPV-associated diseases. Experimental validation is warranted to confirm the inhibitory activity and therapeutic potential of these compounds.
Insights
Researchers discovered novel small molecules targeting human papillomavirus type 16 (HPV16) E6 oncoprotein. These drug-like compounds show promise as antiviral agents for HPV-related cancers, with further validation needed.
Area of Science:
- Computational chemistry
- Drug discovery
- Oncology
Background:
- Human papillomavirus type 16 (HPV16) E6 oncoprotein drives cervical and other cancers.
- Targeting HPV16 E6 with small molecules offers a novel antiviral therapy strategy.
Purpose of the Study:
- Discover and characterize small-molecule inhibitors of HPV16 E6.
- Identify compounds with high affinity, favorable drug-like properties, and inhibitory activity.
Main Methods:
- Integrated molecular dynamics simulations and structure-based virtual screening.
- Evaluated binding stability, interaction patterns, and in silico ADMET properties.
- Utilized molecular docking, MM-GBSA, and MD simulations for analysis.
Main Results:
- Identified nine lead compounds with stable binding to HPV16 E6 (CYS51).
- Confirmed strong theoretical binding affinities and favorable pharmacokinetic profiles for most candidates.
- Two compounds indicated potential toxicity concerns.
Conclusions:
- Developed a computational framework for identifying HPV16 E6 inhibitors.
- Identified promising drug-like candidates for HPV-associated disease treatment.
- Experimental validation is recommended to confirm therapeutic potential.
More Related Videos
13:56A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
Published on: July 18, 2013
06:03Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
